MSD Switzerland Welcomes Young Talents on National Future Day
12.11.2025 08:00 CET
MSD Switzerland Welcomes Young Talents on National Future Day
Lucerne, November 12, 2025 – As part of National Future Day, MSD Switzerland will open its doors tomorrow, November 13, to children in grades 5 to 7, offering them a hands-on and inspiring insight into the world of medical innovation.
At our locations in Lucerne-Tribschen, Schachen (Canton of Lucerne), and Zurich, students will take part in a variety of creative and educational activities that spark curiosity and showcase the diverse career paths at MSD:
- Interactive workshops: In Zurich in English and in Tribschen and Schachen in German, children learn more about MSD, their parents’ work, and how our teams worldwide contribute to improving patient health.
- Behind-the-scenes look: Guided by MSD employees, the children explore our buildings and laboratories and gain insights into drug development as well as the interdisciplinary collaboration of our teams.
- Game “Medicine or Pokémon?”: A playful challenge where children guess whether a name belongs to a medicine or a Pokémon – an entertaining way to learn more about pharmaceutical naming conventions.
- Design challenge: In small teams, children invent a fictional disease, develop a fictional treatment, and present their idea in a short marketing pitch. This activity fosters creativity, teamwork, and scientific thinking.
- Festive cake finale: The day ends with a sweet celebration to honor the children’s creativity and collaboration.
“At MSD, we nurture the next generation of thinkers and innovators,” says Jasper Kunow, Interim Managing Director MSD Switzerland. “National Future Day is a wonderful opportunity to share our enthusiasm for science and health with young people and inspire them.”
About MSD Merck Sharp & Dohme
At MSD Merck Sharp & Dohme, known as Merck & Co., Inc., in Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.
For more information, visit www.msd.com and connect with us on X, LinkedIn et YouTube.
MSD Merck Sharp & Dohme in Switzerland
In Switzerland, MSD Merck Sharp & Dohme employs over 1,000 people at five sites in the cantons of Lucerne and Zurich. At the site in Zurich, in “The Circle”, MSD operates a global innovation and development hub. The main therapeutic areas of MSD are oncology, infectious diseases, and cardiometabolic diseases. We also have a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. At our site in Schachen, we manufacture medicines for global clinical trials and operate a forensic laboratory. In addition, MSD conducts almost 50 clinical trials annually in Switzerland alone. We take our responsibility to the local community seriously and have been involved for years in, among other things, the «Trendtage Gesundheit Luzern» and the «Alliance Health competence». In 2025, MSD received the «Top Employer Switzerland» award for the thirteenth time in a row.
For more information, please visit www.msd.ch, de.msd-animal-health.ch, www.msd-gesundheit.ch and follow us on LinkedIn, Facebook und YouTube.
You can find this and other press releases on our website in the protected area for media professionals: https://www.msd.ch/en/home/news/.
Media Contact
Antonio Ligi
Head of Communications
+41 76 203 44 96
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
CH-NON-03166, 11/2025